Ravoxertinib Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage through Early Inhibition of Erk1/2.

20 To our knowledge, the present study is the first to report the change in the p-Erk1/2 level in CSF from SAH patients, showing an increasing trend on days 1–2 and then a decreasing trend on days 3–4 and days 5–7, and it was elevated in aSAH patients who developed poor outcomes.

also in 47,180 other papers

Using the rat SAH model, this study observed that the p-Erk1/2 level showed an increasing trend at 6 and 12 h and then a decreasing trend in the CSF of rat SAH.

also in 63,971 other papers